U.S. Markets closed

Conformis, Inc. (CFMS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.8050+0.0099 (+1.25%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8600
Open0.8500
Bid0.7910 x 1300
Ask0.8069 x 1000
Day's Range0.7870 - 0.8600
52 Week Range0.5800 - 1.4900
Volume2,667,271
Avg. Volume6,045,061
Market Cap146.855M
Beta (5Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-0.3400
Earnings DateMay 05, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Conformis, Inc. to Present at the Canaccord Genuity Musculoskeletal Conference
    GlobeNewswire

    Conformis, Inc. to Present at the Canaccord Genuity Musculoskeletal Conference

    BILLERICA, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will present at the Canaccord Genuity Musculoskeletal Conference. The virtual presentation is scheduled for Thursday, May 20, 2021 at 10:30 a.m. ET. A live webcast of the presentation will be available at https://wsw.com/webcast/canaccord54/cfms/2442655. Conformis management will also be available for one-on-one meetings throughout the conference. For more information about the conference or to schedule a one-on-one meeting with management, please contact your Canaccord representative or Conformis Investor Relations at ir@conformis.com and (781) 374-5598. The live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Conformis website at ir.conformis.com. The replay of the webcast will be archived on Conformis' website for 30 days following the presentation. About Conformis, Inc. Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit and conform to each patient’s unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints. For more information, visit www.comformis.com. To receive future releases in e-mail alerts, sign up at ir.conformis.com. CONTACT: Investor Contact: ir@conformis.com (781) 374-5598

  • MedTech Round Up: Update On Products By Conformis, Medtronic, Orthofix, Neovasc
    Benzinga

    MedTech Round Up: Update On Products By Conformis, Medtronic, Orthofix, Neovasc

    The FDA has given 510(k) clearance for Conformis Inc's (NASDAQ: CFMS) Identity Imprint Knee Replacement System, available in both cruciate-retaining (CR) and posterior stabilized (PS) versions. Identity Imprint utilizes a proprietary 3-dimensional "best-fit" algorithm to select the implant that most closely meets the geometric and anatomic requirements of the patient based on the patient's computed tomography scans. Price Action: CFMS shares are trading 6.95% higher at $0.90 during the market trading session on the last check Monday. Medtronic plc (NYSE: MDT) has announced the U.S. commercial launch of the SonarMed airway monitoring system, a pediatric monitor to check endotracheal tube (ETT) obstruction and verify position in real-time. SonarMed, which Medtronic acquired in December 2020, specializes in developing solutions that increase patient safety while significantly decreasing healthcare costs. Price Action: MDT shares are up 0.43% at $127.24 during the market trading session on the last check Monday. The FDA has given 510(k) clearance to Orthofix Medical Inc's (NASDAQ: OFIX) OrthoNext digital platform, a software tool for deformity analysis and preoperative planning for pediatric orthopedic procedures. Developed specifically for use with the JuniOrtho Plating System, the OrthoNext digital platform software enables the surgeon to plan the osteotomy position accurately to visualize the implant concerning the anatomy. The company has initiated its U.S. and European full market launch of the JuniOrtho Plating System. Price Action: OFIX shares are down 4.05% at $42.37 during the market trading session on the last check Monday. Neovasc Inc (NASDAQ: NVCN) has enrolled the first patient in the COSIMA trial investigating the company's Reducer for the treatment of Microvascular Angina. The study will enroll up to 144 patients across multiple centers in Germany. The primary endpoint of the study is the change in CCS angina class, a measure of chest pain severity and limitation, by two or more classes. The Reducer is CE-marked in the European Union to treat refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle. Price Action: NVCN shares are down 3.2% at $0.83 during the market trading session on the last check Monday. See Benzinga's FDA Calendar See more from BenzingaClick here for options trades from BenzingaHeron Stock Trading Higher After Q1 Earnings, Ahead Of HTX-011 Decision Scheduled This WeekTaysha Gene Therapies' Rett Syndrome Candidate Shows Encouraging Action In Animal Studies, Human Trial To Start By 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Conformis, Inc. Announces 510(k) Clearance for Identity Imprint™ Knee Replacement System
    GlobeNewswire

    Conformis, Inc. Announces 510(k) Clearance for Identity Imprint™ Knee Replacement System

    Leveraging Conformis’ extensive library of personalized knee design data and patient images, Identity Imprint is designed to match patients’ anatomy with an optimal arthroplasty solution while at the same time offering greater efficiency, cost savings, increased intraoperative flexibility, and faster delivery timesBILLERICA, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) today announced 510(k) clearance by the U.S. Food and Drug Administration for the Company’s Identity Imprint Knee Replacement System. Identity Imprint is a new total knee replacement system, available in both cruciate retaining (CR) and posterior stabilized (PS) versions, that expands the range of options open to Conformis’ orthopedic surgeon customers and their patients. Whereas the Conformis iTotal® Identity knee replacement system is designed and manufactured individually to fit the unique size, shape, and curvature of each patient’s anatomy, Identity Imprint combines pre-determined implant sizes with standard and patient-specific surgical instrumentation. Identity Imprint will provide surgeons with faster delivery times and intraoperative options that are more similar to standard knee systems. Identity Imprint utilizes a proprietary 3-dimensional (3D) “best-fit” algorithm to select the implant that most closely meets the geometric and anatomic requirements of the patient based on the patient’s computed tomography (CT) scans. The Identity Imprint will be delivered using Conformis’ sterile “surgery-in-box” system, which is expected to provide ambulatory surgical centers (ASCs) greater procedural efficiency and improved sterilization cost savings than standard systems. “Our Identity Imprint knee system is a tremendous new addition to our product portfolio that leverages our technical innovations and data from tens of thousands of personalized implant designs. It is a terrific option for those surgeons who want more traditional intraoperative flexibility and faster product availability. We will be able to provide a patient-matched Identity Imprint system in 3 weeks versus the six weeks lead time for the iTotal Identity fully personalized system,” said Mark Augusti, President and CEO. “This offering is extremely well-positioned to meet the needs of the ASC care setting, but will provide value to in-patient hospital care as well, especially in the post-COVID environment. Importantly, it also provides surgeons and their patients a new choice among Conformis’ world-class treatment options.” The global knee joint reconstruction market is projected at over $9 billion, with approximately 1 million knee replacements expected to be performed in the United States this year, with a growing number of knee procedures to be performed in the ASC and outpatient settings. About Conformis, Inc. Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit and conform to each patient’s unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and standard implants, along with single-use instruments delivered to hospitals and ambulatory surgical centers. In clinical studies, the Conformis iTotal® CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints. For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com. Cautionary Statement Regarding Forward-Looking Statements Statements in this press release about our future expectations, plans and prospects, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. You should not place undue reliance on our forward-looking statements. Actual results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof. Source: Conformis, Inc. CONTACT: Media Contact: Investor Relations ir@conformis.com (781) 374-5598